# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Vincent van Gogh (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI010-SYN
- Date: 2026-07-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Elise Verhoeven, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month review: diagnosis, relapse prevention, movement check, and alcohol. **S**

## History of present illness

Mr. van Gogh returns six months after his first visit. He has had no psychotic symptoms for more than four months and no racing ideas since the spring. He takes aripiprazole 10 mg and naltrexone daily. He sleeps seven hours. He is painting every day and preparing work for a small exhibition. He drinks a glass of wine with dinner on some days and none on others. His mood is good. The care coordinator's monthly PHQ-9 calls have been in the low range. He has had no thoughts of suicide or self-harm. His hepatitis C antibody from the preventive visit was nonreactive. **S**

| Element | Detail |
|---|---|
| Psychotic symptoms | None for more than four months |
| Mood | Good; PHQ-9 3 |
| Sleep | Seven hours at regular times |
| Alcohol | A glass of wine with dinner on some days |
| Hepatitis C antibody | Nonreactive |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight stable |
| Neurological | Negative | No restlessness, stiffness, tremor, abnormal movements, or seizures |
| Psychiatric | Negative | No voices, suspiciousness, or racing ideas; mood good; no thoughts of suicide or self-harm |

3 systems reviewed. **S**

## Current medications

- Naltrexone 50 mg oral tablet, one tablet by mouth once daily **S**
- Aripiprazole 10 mg oral tablet, one tablet by mouth once daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/76 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 65.4 kg; BMI 22.6 kg/m². All vital signs are synthetic.

White cells: 6.4 10*3/uL; Hemoglobin: 14.6 g/dL; MCV: 95 fL; Platelets: 214 10*3/uL; AST: 27 U/L; ALT: 26 U/L; GGT: 36 U/L; Phosphatidylethanol (PEth): 16 ng/mL; PHQ-9: 3. All results are synthetic.

## Change since baseline

- White cells: 6.8 10*3/uL at baseline, 6.4 10*3/uL at this visit **S**
- Hemoglobin: 14.2 g/dL at baseline, 14.6 g/dL at this visit **S**
- MCV: 102 fL (high) at baseline, 95 fL at this visit **S**
- Platelets: 172 10*3/uL at baseline, 214 10*3/uL at this visit **S**
- AST: 58 U/L (high) at baseline, 27 U/L at this visit **S**
- ALT: 44 U/L at baseline, 26 U/L at this visit **S**
- GGT: 96 U/L (high) at baseline, 36 U/L at this visit **S**
- Phosphatidylethanol (PEth): 284 ng/mL (high) at baseline, 16 ng/mL at this visit **S**
- PHQ-9: 13 at baseline, 3 at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), dose 2 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 65.4 kg; blood pressure 118/76, pulse 70 |
| Neurological | AIMS score 0: no abnormal movements of the face, lips, jaw, tongue, limbs, or trunk; no akathisia or rigidity |
| Psychiatric | Euthymic and engaged; organized; no psychotic features |

All examination findings are synthetic. **S**

## Assessment and plan

1. **First episode of psychosis with mood features, provisional diagnosis, in remission** (F29). Full remission for more than four months, with no symptoms between, a normal MRI and EEG, and no seizure-like events. This course makes schizophrenia unlikely and leaves bipolar I disorder with psychotic features and a psychosis related to heavy drinking and its sudden withdrawal as the leading possibilities. The diagnosis stays provisional: a manic or depressive episode would point to bipolar disorder, and psychosis without mood change or alcohol would point to a schizophrenia-spectrum disorder. A mood stabilizer would be considered if a mood episode occurs. AIMS score 0. Safety reviewed: no thoughts of suicide or self-harm; the safety plan and psychiatric advance directive are current. **S**
   - Continue aripiprazole 10 mg daily.
   - Decide with him and Dr. Feld near the one-year mark whether and how slowly to reduce it, with a written relapse plan.
   - AIMS again in six months; glucose, A1c and lipids yearly.
2. **Alcohol use disorder on naltrexone** (F10.20). PEth 16 ng/mL, from 284 at intake: light drinking, as he chose. AST 27, ALT 26 and GGT 36 U/L normal; MCV back to 95 fL. **S**
   - Continue naltrexone for at least six more months, then review.
   - Stop thiamine now that drinking is light and meals are regular.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Antipsychotic dose, adherence, and response | Every visit | Completed today | Aripiprazole 10 mg; full adherence; full remission |
| Survey | Psychotic and mood symptoms, and early warning signs | Every visit | Completed today | No psychotic or mood symptoms; no early warning signs |
| Examination | Akathisia, parkinsonism, and sedation | Every visit in the first months and after any dose change | Completed today | None |
| Examination | Abnormal Involuntary Movement Scale (AIMS) | Baseline, then every 6 months | Completed today | AIMS score 0 at six months; repeat in six months |
| Examination | Weight and BMI | Every visit for 6 months after starting, then quarterly (CMID: baseline, 4, 8, and 12 weeks, then quarterly) | Completed today | 65.4 kg, up 2.2% from intake; quarterly from now |
| Examination | Blood pressure | Baseline, 12 weeks, then yearly | Completed today | 118/76 |
| Laboratory | Fasting glucose and A1c | Baseline, 12 weeks to 4 months, then yearly | Up to date | Normal at the three-month visit; next in a year |
| Laboratory | Fasting lipid panel | Baseline, 12 weeks to 4 months, then yearly | Up to date | Normal at the three-month visit; next in a year |
| Survey | Depression measure (PHQ-9) | Monthly during acute treatment, every 2 to 4 weeks in continuation, then periodically | Completed today | PHQ-9 3, from 13 at intake: remission |
| Survey | Mood Disorder Questionnaire | When a new depressive episode is evaluated | Not indicated | No depressive episode now; the possibility of bipolar disorder is followed through the mood history at each visit |
| Survey | Suicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; safety plan and psychiatric advance directive current; the 988 Suicide & Crisis Lifeline in his phone |
| Self-management | Sleep | Every visit | Completed today | Seven hours at regular times |
| Survey | Drinking (AUDIT-C and PEth) | PEth at intake and at each check while drinking continues; AUDIT-C yearly | Completed today | PEth 16 ng/mL; AUDIT-C 3 at the preventive visit |
| Medication safety | Naltrexone: liver tests and opioid exposure | Liver tests before starting, then at 1 to 3 months and every 6 to 12 months | Completed today | AST 27, ALT 26, GGT 36 U/L, normal |
| Laboratory | Blood count | At intake and with liver tests while drinking | Completed today | White cells 6.4, hemoglobin 14.6 g/dL, MCV 95 fL (from 102), platelets 214 |
| Medication safety | Thiamine | While drinking heavily | Completed today | Stopped today |
| Self-management | Hepatitis B vaccine | Two doses at least four weeks apart | Completed today | Dose 2 given today; series complete |
| Self-management | Coordinated specialty care engagement | Ongoing, for up to two to three years | Completed today | Therapist every two weeks; peer specialist monthly; exhibition planned |

## Goal progress

- No return of psychotic symptoms and no readmission through six months, on the lowest effective antipsychotic dose. Outcome by 2026-07-20: No psychotic symptoms since the six-week visit and no admission; aripiprazole 10 mg daily. **S**
- PHQ-9 score below 5 by six months. Outcome by 2026-07-20: PHQ-9 3. **S**
- Reduce drinking to PEth below 20 ng/mL by six months. Outcome by 2026-07-20: PEth 16 ng/mL from 284. **S**
- Weight gain under 5% and normal glucose, A1c and lipids at the 12-week check. Outcome by 2026-04-20: Weight 65.7 kg from 64.0 (2.7%); fasting glucose 94 mg/dL, A1c 5.4%, lipids normal. **S**
- Sleep about seven hours on most nights with regular times by three months. Outcome by 2026-04-20: Seven hours on most nights, in bed by midnight. **S**

## Medication changes

- Stopped: Thiamine 100 mg oral tablet, one tablet by mouth daily (started in hospital) **S**

## Guideline basis

- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020), American Psychiatric Association (American Journal of Psychiatry)
- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018), CANMAT and ISBD (Bipolar Disorders)
- Consensus development conference on antipsychotic drugs and obesity and diabetes (2004), American Diabetes Association, American Psychiatric Association, AACE, and NAASO (Diabetes Care)
- Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026), National Institute of Mental Health
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention

## Follow-up

- Visits every three months with weight and the PHQ-9. Psychiatry review with Dr. Feld near the one-year mark about the length of antipsychotic treatment. AIMS in six months; glucose, A1c and lipids in a year. Influenza and COVID-19 vaccines in the autumn. **S**

